Search Within

Sara Christina Meyer

Formats
  1. Journal Article (6)
  2. Meeting Abstract (3)
Groups
  1. Adult Leukemia (9)
  2. Center for Hematologic Malignancies (9)
  3. Center for Molecular Imaging and Biotechnology (CMIB) (9)
  4. Department of Medicine (9)
  5. Executive Committee, Center for Hematologic Malignancies (9)
  6. GSK Faculty (9)

More Groups

People
  1. Ross Levine (9)
  2. Maria Kleppe (5)
  3. Matthew Keller (4)
  4. Neha Bhagwat (3)
  5. Priya Koppikar (3)
  6. Anna Mckenney (2)

More People

Years
  1. 2017 (1)
  2. 2015 (2)
  3. 2014 (5)
  4. 2013 (1)
Publications
  1. Blood (2)
  2. Clinical Cancer Research (2)
  3. Cancer Cell (1)
  4. Cell Reports (1)
  5. EBioMedicine (1)
  6. Haematologica (1)

More Publications

Publishers
  1. American Association for Cancer Research (2)
  2. American Society of Hematology (2)
  3. Cell Press (2)
  4. Elsevier Inc. (1)
  5. Elsevier Science, Inc. (1)
  6. Ferrata Storti Foundation (1)

Results (9)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Mediator kinase phosphorylation of STAT1 S727 promotes growth of neoplasms with JAK-STAT activation
    Journal Article

    Nitulescu, I. I.; Meyer, S. C.; Wen, Q. J.; Crispino, J. D.; Lemieux, M. E.; Levine, R. L.; Pelish, H. E.; Shair, M. D.
    EBioMedicine (2017)

    Fulltext@MSK | Save
  • Role of JAK-STAT pathway activation in MPN pathogenesis and therapeutic response
    Meeting Abstract

    Meyer, S.; Kleppe, M.; Bhagwat, N.; Koppikar, P.; Kwak, M.; Radimerski, T.; Fan, R.; Levine, R. L.
    Clinical Cancer Research (2015)

    Fulltext@MSK | Save
  • CHZ868, a type II JAK2 inhibitor, reverses type I JAK inhibitor persistence and demonstrates efficacy in myeloproliferative neoplasms
    Journal Article

    Meyer, S.; Keller, M.; Chiu, S.; Koppikar, P.; Guryanova, O.; Rapaport, F.; Xu, K.; Manova, K.; Pankov, D.; O'reilly, R.; more...
    Cancer Cell (2015)

    Fulltext@MSK | Save
  • Type II inhibition of JAK2 with NVP-CHZ868 reverses type I JAK inhibitor persistence and demonstrates increased efficacy in MPN models
    Meeting Abstract

    Meyer, S. C.; Keller, M. D.; Koppikar, P.; Guryanova, O. A.; Kleppe, M.; McKenney, A. S.; Sellers, W. R.; Hofmann, F.; Baffert, F.; Gaul, C.; more...
    Blood (2014)

    Fulltext@MSK | Save
  • Genetic studies reveal Jak2 is not essential for platelet production
    Meeting Abstract

    Meyer, S. C.; Keller, M. D.; Woods, B. A.; LaFave, L. M.; Bastian, L.; Kleppe, M.; Bhagwat, N.; Marubayashi, S.; Levine, R. L.
    Haematologica (2014)

    Fulltext@MSK | Save
  • Genetic studies reveal an unexpected negative regulatory role for jak2 in thrombopoiesis
    Journal Article

    Meyer, S. C.; Keller, M. D.; Woods, B. A.; LaFave, L. M.; Bastian, L.; Kleppe, M.; Bhagwat, N.; Marubayashi, S.; Levine, R. L.
    Blood (2014)

    Fulltext@MSK | Save
  • Translational implications of somatic genomics in acute myeloid leukaemia
    Journal Article

    Meyer, S. C.; Levine, R. L.
    Lancet Oncology (2014)

    Fulltext@MSK | Save
  • Molecular pathways: Molecular basis for sensitivity and resistance to JAK kinase inhibitors
    Journal Article

    Meyer, S. C.; Levine, R. L.
    Clinical Cancer Research (2014)

    Fulltext@MSK | Save
  • Combined Targeting of JAK2 and Bcl-2/Bcl-xL to Cure Mutant JAK2-Driven Malignancies and Overcome Acquired Resistance to JAK2 Inhibitors
    Journal Article

    Waibel, M.; Solomon, V. S.; Knight, D. A.; Ralli, R. A.; Kim, S. K.; Banks, K. M.; Vidacs, E.; Virely, C.; Sia, K. C. S.; Bracken, L. S.; more...
    Cell Reports (2013)

    Fulltext@MSK | Save